Zacks Investment Research upgraded shares of XOMA (NASDAQ:XOMA) from a hold rating to a buy rating in a research note published on Saturday morning, Zacks.com reports. The firm currently has $27.00 target price on the biotechnology company’s stock.
According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “
Several other brokerages also recently commented on XOMA. TheStreet upgraded shares of XOMA from a d+ rating to a c rating in a report on Tuesday, November 12th. ValuEngine downgraded shares of XOMA from a hold rating to a sell rating in a report on Friday, January 10th. Finally, HC Wainwright reiterated a buy rating and issued a $30.00 target price on shares of XOMA in a report on Friday, December 6th. One analyst has rated the stock with a sell rating and three have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $27.33.
XOMA traded up $0.75 during trading on Friday, hitting $24.60. 56,804 shares of the company’s stock were exchanged, compared to its average volume of 80,594. The company has a quick ratio of 4.37, a current ratio of 4.37 and a debt-to-equity ratio of 1.31. The business’s 50 day moving average is $25.54 and its two-hundred day moving average is $20.64. XOMA has a fifty-two week low of $11.50 and a fifty-two week high of $28.85. The stock has a market cap of $208.74 million, a P/E ratio of -60.00 and a beta of 1.23.
XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.68. XOMA had a negative net margin of 10.19% and a negative return on equity of 8.93%. The firm had revenue of $8.86 million for the quarter. On average, sell-side analysts forecast that XOMA will post -0.21 earnings per share for the current year.
In other XOMA news, major shareholder Bvf Partners L. P/Il acquired 373,195 shares of XOMA stock in a transaction on Thursday, December 19th. The shares were purchased at an average cost of $22.00 per share, with a total value of $8,210,290.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James R. Neal sold 4,348 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $22.00, for a total transaction of $95,656.00. Following the sale, the chief executive officer now owns 22,017 shares in the company, valued at $484,374. The disclosure for this sale can be found here. Company insiders own 9.89% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Paloma Partners Management Co purchased a new stake in XOMA during the 2nd quarter valued at approximately $510,000. Marshall Wace LLP acquired a new position in shares of XOMA during the second quarter valued at about $434,000. Morgan Stanley grew its stake in shares of XOMA by 2,151.6% during the second quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 22,828 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in XOMA in the third quarter worth $244,000. 37.20% of the stock is currently owned by institutional investors and hedge funds.
XOMA Company Profile
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
Recommended Story: How is the discount rate different from the Federal Funds rate?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.